Antimicrobial-resistant Shigella sonnei: Limited antimicrobial treatment options for children and challenges of interpreting in vitro azithromycin susceptibility

Pediatric Infectious Disease Journal

Volumn 24, Issue 6, 2005, Pages 494-497

  Jain, Sanjay K ^a,b   Gupta, Amita ^a   Glanz, Brian ^a   Dick, James ^a   Siberry, George K ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Pediatric Infectious Diseases   (United States)

Author keywords

Antimicrobial resistance; Azithromycin; Children; E test; Shigella sonnei

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIINFECTIVE AGENT; AZITHROMYCIN; CEFIXIME; CEFOTAXIME; CEFTRIAXONE; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; NALIDIXIC ACID;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM ISOLATE; EPIDEMIC; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; SHIGELLA SONNEI; SHIGELLOSIS; UNITED STATES;

EID: 20744455251     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000164707.13624.a7     Document Type: Article

References (32)

1. Kotloff KL, Winickoff JP, Ivanoff B, et al. Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bull World Health Organ. 1999;77:651-666.
2. Gupta A, Polyak CS, Bishop RD, Sobel J, Mintz ED. Laboratory-confirmed shigellosis in the United States, 1989-2002: epidemiologic trends and patterns. Clin Infect Dis. 2004;38:1372-1377.
3. Mahoney FJ, Farley TA, Burbank DF, Leslie NH, McFarland LM. Evaluation of an intervention program for the control of an outbreak of shigellosis among institutionalized persons. J Infect Dis. 1993;168: 1177-1180.
4. DuPont HL. Shigella species (bacillary dysentery). In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 5th ed. vol 2. New York, NY: Churchill Livingstone; 2000:2363-2369.
5. Tauxe RV, Puhr ND, Wells JG, Hargrett-Bean N, Blake PA. Antimicrobial resistance of Shigella isolates in the USA: the importance of international travelers. J Infect Dis. 1990;162:1107-1111.
6. Replogle ML, Fleming DW, Cieslak PR. Emergence of antimicrobial-resistant shigellosis in Oregon. Clin infect Dis. 2000;30:515-519.
7. Centers for Disease Control and Prevention. NARMS 2001 Annual Report: antimicrobial resistance of Salmonella, Shigella, and E. coli O157 isolates, 2001. Available at: http://www.cdc.gov/narms/annual/2001/table/0104.htm. Accessed June 15, 2004.
8. American Academy of Pediatrics. Shigella infections. In: Pickering LK, ed. Red Book: 2003 Report of the Committee on Infections Diseases. 26th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2003:552-553.
9. Guerrant RL, Gilder TV, Steiner TS, et al. Practice guidelines for the management of infectious diarrhea. Clin Infect Dis. 2001;32:331-350.
10. Khan WA, Seas C, Dhar U, Salam MA, Bennish ML. Treatment of shigellosis, V: comparison of azithromycin and ciprofloxacin: a double-blind, randomized, controlled trial. Ann Intern Med. 1997;126:697-703.
11. Basualdo W, Arbo A. Randomized comparison of azithromycin versus cefixime for treatment of shigellosis in children. Pediatr Infect Dis J. 2003;22:374-377.
12. Bopp CA, Brenner FW, Fields PI, Wells JG, Strockbine NA. Escherichia, Shigella, and Salmonella. In: Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Yolken RH, eds. Manual of Clinical Microbiology. 8th ed. Washington, DC: ASM Press; 2003:654-671.
13. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing; Fourteenth Informational Supplement. Wayne, PA: National Committee for Clinical Laboratory Standards; 2004:19087-191898.
14. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard. 6th ed. Wayne, PA: National Committee for Clinical Laboratory Standards; 2004:19087-191898.
15. Stock I, Wiedemann B. Natural antibiotic susceptibility of Escherichia coli, Shigella, E. vulneris, and E. hermannii strains. Diagn Microbiol Infect Dis. 1999;33:187-199.
16. Centers for Disease Control and Prevention. PHLIS surveillance data: Shigella annual summary 2002. Available at: http://www.cdc.gov/ncidod/dbmd/ phlisdata/shigtab/2002/ShigellaAnnualSummary2002.pdf. Accessed November 11, 2004.
17. Khan WA, Dhar U, Salam MA, Griffiths JK, Rand W, Bennish ML. Central nervous system manifestations of childhood shigellosis: prevalence, risk factors, and outcome. Pediatrics. 1999;103:E18.
18. Kavaliotis J, Karyda S, Konstantoula T, Kansouzidou A, Tsagaropoulou H. Shigellosis of childhood in northern Greece: epidemiological, clinical, and laboratory data of hospitalized patients during the period 1971-1996. Scand J Infect Dis. 2000;32:207-211.
19. Varsano I, Eidlitz-Marcus T, Nussinovitch M, Elian I. Comparative efficacy of ceftriaxone and ampicillin for treatment of severe shigellosis in children. J Pediatr. 1991;118:627-632.
20. Leibovitz E, Janco J, Piglansky L, et al. Oral ciprofioxacin vs. intramuscular ceftriaxone as empiric treatment of acute invasive diarrhea in children. Pediatr Infect Dis J. 2000;19:1060-1067.
21. Eidlitz-Marcus T, Cohen YH, Nussinovitch M, Elian I, Varsano I. Comparative efficacy of two- and five-day courses of ceftriaxone for treatment of severe shigellosis in children. J Pediatr. 1993;123:822-824.
22. Parry HE. Oral kanamycin in the treatment of Shigella and Salmonella infections. Postgrad Med J. 1967;suppl:7-13.
23. Islam MR, Alam AN, Hossain MS, Mahalanabis D, Hye HK. Double-blind comparison of oral gentamicin and nalidixic acid in the treatment of acute shigellosis in children. J Trop Pediatr. 1994;40:320-325.
24. Landa L. Cephradine in the treatment of intestinal infections caused by Shigella or Salmonella organisms. Curr Ther Res Clin Exp. 1972;14: 496-502.
25. Orenstein WA, Ross L, Overturf GD, Wilkins J, Redfield DR, Underman A. Antibiotic treatment of acute shigellosis: failure of cefamandole compared with trimethoprim/sulfamethoxazole and ampicillin. Am J Med Sci. 1981; 282:27-33.
26. Ostrower VG. Comparison of cefaclor and ampicillin in the treatment of shigellosis. Postgrad Med J. 1979;55(suppl 4):82-84.
27. Ashkenazi S, Amir J, Waisman Y, et al. Randomized, double-blind study comparing cefixime and trimethoprim-sulfamethoxazole in the treatment of childhood shigellosis. J Pediatr. 1993;123:817-821.
28. Martin JM, Pitetti R, Maffei F, Tritt J, Smail K, Wald ER. Treatment of shigellosis with cefixime: two days vs. five days. Pediatr Infect Dis J. 2000;19:522-526.
29. Salam MA, Seas C, Khan WA, Bennish ML, Therapy for shigellosis, IV: cefixime is ineffective in shigellosis in adults. Ann Intern Med. 1995; 123:505-508.
30. Salam MA, Bennish ML. Therapy for shigellosis. I. Randomized, double-blind trial of nalidixic acid in childhood shigellosis. J Pediatr. 1988;113:901-907.
31. Miron D, Torem M, Merom R, Colodner R. Azithromycin as an alternative to nalidixic acid in the therapy of childhood shigellosis. Pediatr Infect Dis J. 2004;23:367-368.
32. Schentag JJ, Ballow CH. Tissue-directed pharmacokinetics. Am J Med. 1991;12:91:5S-11S.